Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.85. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | JNK | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $98.19 |
52-Week Low | $110.56 | $94.66 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
JNK trades at $95.85, up 0.21% with a bearish technical signal from moving averages and oscillators neutral. Recent news highlights bond market volatility amid inflation data and Middle East tensions, with Fitch Ratings warning of AI-related corporate credit risks. The ETF maintains dividend distributions, with recent payouts around $0.52-$0.53.
Outlook is cautious due to macroeconomic headwinds and credit risks, but higher yields may attract income investors. Key risks include Fed policy uncertainty and oil price fluctuations impacting bond markets. Analyst sentiment is mixed, balancing yield appeal against fee concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
